Canaccord Genuity Group Cuts Omada Health (NASDAQ:OMDA) Price Target to $22.00

by · The Cerbat Gem

Omada Health (NASDAQ:OMDA – Get Free Report) had its target price cut by stock analysts at Canaccord Genuity Group from $28.00 to $22.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 56.92% from the company’s current price.

Other research analysts also recently issued research reports about the company. Wells Fargo & Company assumed coverage on Omada Health in a report on Thursday, January 8th. They issued an “equal weight” rating and a $17.00 price objective on the stock. Evercore raised their price objective on shares of Omada Health from $27.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. The Goldman Sachs Group restated a “buy” rating and issued a $26.00 target price on shares of Omada Health in a report on Friday, January 16th. Morgan Stanley cut their price target on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Barclays decreased their price objective on shares of Omada Health from $22.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.90.

Get Our Latest Stock Report on Omada Health

Omada Health Stock Performance

Shares of OMDA traded up $0.42 during mid-day trading on Friday, hitting $14.02. 4,178,368 shares of the company’s stock were exchanged, compared to its average volume of 1,287,286. The stock’s 50-day moving average is $14.07 and its 200-day moving average is $18.73. Omada Health has a fifty-two week low of $10.28 and a fifty-two week high of $28.40. The company has a market cap of $811.90 million and a price-to-earnings ratio of -56.08.

Omada Health (NASDAQ:OMDA – Get Free Report) last released its earnings results on Thursday, March 5th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.12. The company had revenue of $75.85 million for the quarter.

Insider Transactions at Omada Health

In related news, President Wei-Li Shao sold 5,618 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $16.13, for a total value of $90,618.34. Following the transaction, the president owned 69,079 shares in the company, valued at $1,114,244.27. The trade was a 7.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Sean P. Duffy sold 230,479 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.60, for a total value of $3,595,472.40. Following the sale, the chief executive officer directly owned 126,644 shares of the company’s stock, valued at $1,975,646.40. The trade was a 64.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 276,893 shares of company stock worth $4,336,787.

Institutional Trading of Omada Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cigna Investments Inc. New purchased a new position in Omada Health during the third quarter worth about $76,161,000. Perceptive Advisors LLC acquired a new position in Omada Health during the 2nd quarter worth approximately $44,402,000. Millennium Management LLC raised its stake in shares of Omada Health by 1,195.0% during the 4th quarter. Millennium Management LLC now owns 2,272,168 shares of the company’s stock worth $35,855,000 after buying an additional 2,096,705 shares in the last quarter. Divisadero Street Capital Management LP acquired a new stake in shares of Omada Health in the 3rd quarter valued at approximately $30,510,000. Finally, Loomis Sayles & Co. L P purchased a new stake in shares of Omada Health in the second quarter valued at approximately $19,948,000.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

  • Positive Sentiment: Q4 beat and improving profitability — Omada reported $0.08 EPS vs. ($0.04) consensus and $75.85M revenue; Q4 revenue +58% YoY, member growth +55%, positive Q4 net income and full-year positive adjusted EBITDA. Omada Health Reports Fourth Quarter and Full-Year 2025 Results
  • Positive Sentiment: New product launches and growth target — Omada launched GLP-1 Flex Care and new GLP-1/cholesterol programs and outlined a 22% revenue growth target for 2026, which supports recurring revenue expansion and employer uptake. Omada outlines 22% revenue growth target & launches GLP-1 programs
  • Positive Sentiment: Wall Street support remains — Goldman Sachs maintained a Buy rating with a $26 price target, signaling continued analyst conviction despite mixed PT moves elsewhere. Goldman maintains Buy on Omada
  • Neutral Sentiment: FY2026 revenue guidance roughly in line with consensus — Company issued revenue guidance of $312M–$322M vs. consensus ~$312.2M; guidance is broadly in line but execution will matter. FY2026 guidance (press release)
  • Neutral Sentiment: Morgan Stanley trimmed its PT modestly from $32 to $30 but kept an Overweight rating — still implies sizable upside, so this is less negative than a rating downgrade. Morgan Stanley price-target note
  • Negative Sentiment: BMO cut its price target sharply from $27 to $18 (Outperform) — a notable reduction in upside expectations that may cap near-term analyst-driven gains. BMO lowers Omada price target
  • Negative Sentiment: Barclays lowered its PT to $17 — another downgrade to analysts’ absolute target levels that increases headline risk despite operational momentum. Barclays lowers Omada target

Omada Health Company Profile

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Featured Articles